‘Survive To Thrive’ Becomes Mantra In Altered VC Landscape
This article was originally published in The Pink Sheet Daily
Deal designs and investor demands are changing, venture capitalists find – but major innovations can still win.
You may also be interested in...
“Year or two” of pre-IND work lies ahead with new amyloid approach, CEO says.
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.